Clinical TrialsORKA-002 trial begins dosing subjects ahead of schedule, highlighting efficient progress in clinical development.
Financial HealthThe company ended the quarter with $373M in cash and equivalents, providing a financial runway through 2027.
Product DevelopmentOruka is the first company to use PASI 100 as a primary endpoint in a psoriasis trial, indicating a potentially innovative approach.